

Georgia M Beasley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/663998/publications.pdf>

Version: 2024-02-01

103
papers

2,035
citations

236925

25
h-index

289244

40
g-index

112
all docs

112
docs citations

112
times ranked

1884
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and tumor characteristics of patients presenting with single primary versus second primary melanoma lesions. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1033-1039.	1.2	2
2	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	3.3	3
3	How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent. <i>Journal of Surgical Oncology</i> , 2022, 125, 712-718.	1.7	3
4	Diversity Among Surgical Faculty, Residents, and Oncology Fellows from 2011/2012 to 2019/2020. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	5
5	Oncolytic viruses in melanoma. <i>Frontiers in Bioscience</i> , 2022, 27, 063.	2.1	12
6	Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. <i>Journal of Surgical Oncology</i> , 2022, 125, 28-33.	1.7	1
7	ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
8	Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	4
9	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	0
10	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9510-9510.	1.6	22
11	Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1287-1295.	7.0	2
12	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3501-3510.	1.5	13
13	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.5	14
14	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	1.5	8
15	Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 475-483.	4.2	6
16	Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients?. <i>Annals of Surgical Oncology</i> , 2021, 28, 3452-3454.	1.5	0
17	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. <i>Nature Communications</i> , 2021, 12, 1858.	12.8	47
18	Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. , 2021, 9, e002203.		44

#	ARTICLE	IF	CITATIONS
19	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT2). <i>Cancer</i> , 2021, 127, 2251-2261.	4.1	37
20	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	1.5	8
21	Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9576-9576.	1.6	0
22	Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9510-9510.	1.6	6
23	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. <i>Cell Reports</i> , 2021, 35, 109071.	6.4	35
24	Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer. <i>JID Innovations</i> , 2021, 1, 100043.	2.4	2
25	ASO Author Reflections: Gene Expression-Profiling and Implications for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3511-3511.	1.5	1
26	Trends in Racial, Ethnic, and Sex Representation Among Surgical Faculty Members and Medical Students in the US, 2011-2020. <i>JAMA Surgery</i> , 2021, 156, 1177.	4.3	6
27	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110535.	1.8	7
28	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 35-42.	1.5	4
29	Melanomas of Unknown Primary May Have a Distinct Molecular Classification to Explain Differences in Patient Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 4870-4871.	1.5	3
30	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146.	1.0	8
31	Retreatment with talimogene laherparepvec for advanced melanoma. <i>Immunotherapy</i> , 2020, 12, 1167-1172.	2.0	1
32	Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. <i>Anticancer Research</i> , 2020, 40, 5245-5254.	1.1	14
33	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	1.5	8
34	The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. <i>Surgical Oncology</i> , 2020, 35, 533-539.	1.6	4
35	Acral Melanomas of the Sole May Have Worse Prognosis Compared with Other Sites of Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3121-3122.	1.5	3
36	ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 5126-5127.	1.5	0

#	ARTICLE	IF	CITATIONS
37	The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5259-5266.	1.5	5
38	Injectable Therapies for Regional Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 433-444.	1.5	5
39	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429.	1.5	10
40	Mind the gap: Gendered publication trends in oncology. <i>Cancer</i> , 2020, 126, 2859-2865.	4.1	34
41	Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis. <i>Oncology and Therapy</i> , 2020, 8, 261-275.	2.6	9
42	Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 5121-5125.	1.5	19
43	Multimomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies. <i>Journal of Clinical Oncology</i> , 2020, 38, e22015-e22015.	1.6	1
44	Type of Organ Transplanted Impacts the Risk and Presentation of Cutaneous Squamous Cell Carcinoma in Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , 2020, 18, 93-97.	0.5	2
45	302- A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma. , 2020, , .		0
46	425- Investigation of Wnt ligand signaling regulators as a predictor of Anti-PD-1 response in metastatic melanoma. , 2020, , .		1
47	The impact of transplant rejection on cutaneous squamous cell carcinoma in renal transplant recipients. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 265-269.	1.3	1
48	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3962-3971.	1.5	5
49	Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. <i>Annals of Surgical Oncology</i> , 2019, 26, 4633-4641.	1.5	24
50	Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	4.8	44
51	Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	1.5	35
52	The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. <i>Journal of Surgical Research</i> , 2019, 236, 209-215.	1.6	24
53	Updates in adjuvant systemic therapy for melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 222-231.	1.7	35
54	Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?. <i>Journal of Surgical Oncology</i> , 2018, 117, 1584-1588.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Contemporary Approaches to In-Transit Melanoma. <i>Journal of Oncology Practice</i> , 2018, 14, 292-300.	2.5	25
56	Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 55.	3.0	20
57	Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 487-495.	1.8	7
58	Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2728-2733.	1.5	27
59	Surveillance strategies in the follow-up of melanoma patients: too much or not enough?. <i>Journal of Surgical Research</i> , 2017, 214, 32-37.	1.6	31
60	Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. <i>International Journal of Surgery Oncology</i> , 2017, 2, e43-e43.	0.2	5
61	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. <i>Clinical Skin Cancer</i> , 2016, 1, 75-81.	0.1	7
62	Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1090-1095.	1.5	3
63	Targeting N-cadherin Increases Vascular Permeability and Differentially Activates AKT in Melanoma. <i>Annals of Surgery</i> , 2015, 261, 368-377.	4.2	15
64	Procedure Delegation by Attending Surgeons Performing Concurrent Operations in Academic Medical Centers. <i>Annals of Surgery</i> , 2015, 261, 1044-1045.	4.2	56
65	Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 482-488.	1.5	36
66	A Multicenter Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2015, 22, 287-294.	1.5	24
67	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 358-360.	1.5	14
68	Age and gender differences in substance screening may underestimate injury severity: a study of 9793 patients at level 1 trauma center from 2006 to 2010. <i>Journal of Surgical Research</i> , 2014, 188, 190-197.	1.6	14
69	Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1024-1030.	1.5	4
70	Resection of Residual Disease after Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 650-655.	1.5	23
71	Hypoxia in Melanoma: Using Optical Spectroscopy and EF5 to Assess Tumor Oxygenation Before and During Regional Chemotherapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1435-1440.	1.5	8
72	Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2525-2531.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Efficacy of Repeat Sentinel Lymph Node Biopsy in Patients Who Develop Recurrent Melanoma. <i>Journal of the American College of Surgeons</i> , 2014, 218, 686-692.	0.5	32
74	Plasma Cytokine Analysis in Patients with Advanced Extremity Melanoma Undergoing Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2013, 20, 1128-1135.	1.5	21
75	Simultaneous Diaphragm and Liver Resection: A Propensity-Matched Analysis of Postoperative Morbidity. <i>Journal of the American College of Surgeons</i> , 2013, 216, 402-411.	0.5	10
76	Predicting Disease Progression After Regional Therapy for In-Transit Melanoma. <i>JAMA Surgery</i> , 2013, 148, 493.	4.3	10
77	Type III TGF- β 2 receptor downregulation generates an immunotolerant tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2013, 123, 3925-3940.	8.2	94
78	HEPATIC ABSCESS. , 2013, , 35-45.		0
79	Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3328-3339.	7.0	51
80	A Multicenter Prospective Evaluation of the Clinical Utility of F-18 FDG-PET/CT in Patients With AJCC Stage IIIB or IIIC Extremity Melanoma. <i>Annals of Surgery</i> , 2012, 256, 350-356.	4.2	36
81	A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2012, 19, 3896-3905.	1.5	22
82	Patterns of Recurrence Following Complete Response to Regional Chemotherapy for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 2563-2571.	1.5	18
83	A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. <i>Cancer</i> , 2012, 118, 6136-6143.	4.1	14
84	A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities. <i>Annals of Surgical Oncology</i> , 2012, 19, 1637-1643.	1.5	40
85	Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1383-1394.	3.3	7
86	Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. <i>Archives of Surgery</i> , 2011, 146, 870.	2.2	38
87	Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2011, 213, 306-316.	0.5	91
88	Standardizing Regional Therapy: Developing a Consensus on Optimal Utilization of Regional Chemotherapy Treatments in Melanoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 1814-1818.	1.5	6
89	Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1210-1215.	1.6	73
90	Treatment of in-transit melanoma: an opportunity to discover critical knowledge. <i>Oncology</i> , 2011, 25, 1351-2, 1355.	0.5	2

#	ARTICLE	IF	CITATIONS
91	Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2090-2101.	4.1	45
92	What's New in Neoadjuvant Therapy for Breast Cancer?. <i>Advances in Surgery</i> , 2010, 44, 199-228.	1.3	8
93	A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US. <i>Journal of the American College of Surgeons</i> , 2009, 208, 706-715.	0.5	132
94	A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. <i>Cancer</i> , 2009, 115, 4766-4774.	4.1	53
95	Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity?. <i>Annals of Surgical Oncology</i> , 2009, 16, 953-961.	1.5	45
96	Optimizing Regional Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 1095-1097.	1.5	3
97	Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis. <i>Annals of Surgical Oncology</i> , 2009, 16, 2570-2578.	1.5	55
98	Optimizing regional infusion treatment strategies for melanoma of the extremities. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1599-1609.	2.4	14
99	Surgical Excision of Infected Arteriovenous Grafts: Technique and Review. <i>Journal of Vascular Access</i> , 2009, 10, 148-152.	0.9	6
100	Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion. <i>Annals of Surgical Oncology</i> , 2008, 15, 2195-2205.	1.5	144
101	Current Clinical and Research Approaches to Optimizing Regional Chemotherapy: Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 731-758.	1.5	7
102	Future directions in regional treatment strategies for melanoma and sarcoma. <i>International Journal of Hyperthermia</i> , 2008, 24, 301-309.	2.5	19
103	A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 9013-9013.	1.6	5